<DOC>
	<DOCNO>NCT01042574</DOCNO>
	<brief_summary>This study single-arm , open label protocol evaluate use Cleviprex rapidly control hypertension patient present intracerebral hemorrhage ( ICH ) subarachnoid hemorrhage ( SAH ) , require ICP monitoring via ventriculostomy ( External Ventricular Drain EVD ) .</brief_summary>
	<brief_title>The Efficacy Safety Cleviprex Ventriculostomy Patients Requiring IV Antihypertensive Therapy</brief_title>
	<detailed_description>Inclusion Criteria : The study population comprise men non-pregnant woman age 18 year old present ICH SAH require ICP monitoring via ventriculostomy , require IV antihypertensive therapy ) reduce risk re-bleeding SAH b ) reduce risk hematoma expansion time due bleeding . This study population require rapid sustained tight control blood pressure 110 140 mmHg . Subjects may include study meet follow criterion : 1 . Age 18 year old 2 . Patient presentation ICH SAH , require ICP monitoring via ventriculostomy drain . 3 . Baseline systolic blood pressure ( immediately prior initiation Cleviprex ) &gt; 160 mmHg measure 4 . Requires IV antihypertensive therapy achieve SBP 110 - 140 mmHg 5 . Patients life expectancy &gt; 5 hour . 6 . Written informed consent patient legal representative initiation study specific procedure Exclusion Criteria : Subjects exclude study follow exclusion criterion apply prior enrollment : 1 . Receipt oral antihypertensive within 2 hour prior initiation Cleviprex 2 . Receipt IV nicardipine 3 . Glasgow coma score ( GCS ) &lt; 5 fix dilate pupil 4 . Expectation patient tolerate require &gt; 5 hour concurrent Cleviprex treatment ICP monitoring 5 . Known suspected aortic dissection 6 . Acute myocardial infarction ( AMI ) presentation 7 . Positive pregnancy test , know pregnancy nurse mother 8 . Intolerance allergy calcium channel blocker 9 . Allergy soybean oil egg lecithin 10 . Known liver failure , cirrhosis pancreatitis 11 . Defective lipid metabolism 12 . Severe aortic stenosis 13 . Prior directives advanced life support 14 . Participation clinical research study involve evaluation investigational drug device within 30 day enrollment Patients exclude reason may re-screened participation time exclusion characteristic change .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Subarachnoid Hemorrhage</mesh_term>
	<mesh_term>Intracranial Hemorrhages</mesh_term>
	<mesh_term>Antihypertensive Agents</mesh_term>
	<mesh_term>Clevidipine</mesh_term>
	<criteria>1 . Age 18 year old 2 . Patient presentation ICH SAH , require ICP monitoring via ventriculostomy drain . 3 . Baseline systolic blood pressure ( immediately prior initiation Cleviprex ) &gt; 160 mmHg measure 4 . Requires IV antihypertensive therapy achieve SBP 110 140 mmHg 5 . Patients life expectancy &gt; 5 hour . 6 . Written informed consent patient legal representative initiation study specific procedures 1 . Receipt oral antihypertensive within 2 hour prior initiation Cleviprex 2 . Receipt IV nicardipine 3 . Glasgow coma score ( GCS ) &lt; 5 fix dilate pupil 4 . Expectation patient tolerate require &gt; 5 hour concurrent Cleviprex treatment ICP monitoring 5 . Known suspected aortic dissection 6 . Acute myocardial infarction ( AMI ) presentation 7 . Positive pregnancy test , know pregnancy nurse mother 8 . Intolerance allergy calcium channel blocker 9 . Allergy soybean oil egg lecithin 10 . Known liver failure , cirrhosis pancreatitis 11 . Defective lipid metabolism 12 . Severe aortic stenosis 13 . Prior directives advanced life support 14 . Participation clinical research study involve evaluation investigational drug device within 30 day enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>intracranial hemorrhage ( ICH )</keyword>
	<keyword>subarachnoid hemorrhage ( SAH )</keyword>
	<keyword>intracranial monitoring</keyword>
	<keyword>external ventricular drain ( ventriculostomy )</keyword>
	<keyword>hypertension</keyword>
</DOC>